Innovent Biologics (suzhou) Co. Ltd.

This early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune system attacks. The study first checks safety in 160 healthy adults, then in people with active vitiligo or severe alopecia areata. Participants receive either the drug or a …

This study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants w…

This early-stage trial is testing a new drug called IBI115, alone or with other treatments, in 150 people with advanced small cell lung cancer. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants will receive the drug for …

This Phase 2 study tests a new drug called IBI343 combined with two standard chemotherapies (gemcitabine and nab-paclitaxel) in about 389 people with advanced stomach or pancreatic cancers that have a specific protein (CLDN18.2). The main goals are to see if the combination shrin…

This study tests a drug called IBI362 in 180 Chinese adolescents aged 12 to 17 who are obese or overweight and haven't lost enough weight with diet and exercise alone. Participants will receive either the drug or a placebo to see if it helps reduce body mass index (BMI) safely. T…

This phase 2 trial tests whether adding an experimental immunotherapy (IBI363) or the approved drug Keytruda to chemotherapy before surgery can improve outcomes for people with stage IB to III non-squamous non-small cell lung cancer. About 170 participants will receive either IBI…

This Phase 3 trial tests a drug called IBI362 in people with mild to moderate high blood pressure who are also overweight or obese. Participants receive weekly injections of either the drug or a placebo for 48 weeks. The main goal is to see if IBI362 lowers blood pressure more th…

This study tests a new medicine called IBI356 for adults with moderate to severe atopic dermatitis (eczema). About 403 participants will receive either the drug or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to control the disease and improv…

This Phase 3 trial tests a new injectable drug called IBI306 in 198 Chinese adults with non-familial high cholesterol and mixed high lipids. Participants receive either IBI306 or a placebo every 2 or 4 weeks for 12 weeks. The main goal is to see how much the drug lowers LDL (bad)…

This early-phase trial is testing an experimental drug called IBI3014 in 250 adults with advanced solid tumors that cannot be surgically removed. The study aims to find the safest dose and check whether the drug can shrink tumors. Participants receive IBI3014 by IV every three we…

This study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…

This study tests a new drug called IBI311 for people with inactive thyroid eye disease, a condition that causes the eyes to bulge. The goal is to see if the drug can safely reduce eye bulging. About 111 adults will take either IBI311 or a placebo for up to 64 weeks, and doctors w…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive eith…